These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 19959103

  • 21. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse.
    Wang ES, Sait SN, Gold D, Mashtare T, Starostik P, Ford LA, Wetzler M, Nowak NJ, Deeb G.
    Cancer Genet Cytogenet; 2010 Oct 15; 202(2):101-7. PubMed ID: 20875872
    [Abstract] [Full Text] [Related]

  • 22. Clinical implications of non-A-type NPM1 and FLT3 mutations in patients with normal karyotype acute myeloid leukemia.
    Park BG, Chi HS, Park SJ, Min SK, Jang S, Park CJ, Kim DY, Lee JH, Lee JH, Lee KH.
    Acta Haematol; 2012 Oct 15; 127(2):63-71. PubMed ID: 22104247
    [Abstract] [Full Text] [Related]

  • 23. Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation.
    Mori Y, Yoshimoto G, Kumano T, Miyamoto T, Iino T, Takenaka K, Iwasaki H, Harada N, Kinukawa N, Nagafuji K, Teshima T, Shimoda K, Akashi K, Harada M.
    Eur J Haematol; 2007 Jul 15; 79(1):17-24. PubMed ID: 17598835
    [Abstract] [Full Text] [Related]

  • 24. [THE CLINICAL SIGNIFICANCE OF GENETIC MUTATIONS IN ACUTE MYELOID LEUKEMIA].
    Goryainova NV.
    Lik Sprava; 2014 Dec 15; (12):10-8. PubMed ID: 26638462
    [Abstract] [Full Text] [Related]

  • 25. [Acute myeloid leukemia].
    Watanabe R.
    Rinsho Ketsueki; 2009 Mar 15; 50(3):154-9. PubMed ID: 19352081
    [No Abstract] [Full Text] [Related]

  • 26. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics.
    Gaidzik V, Döhner K.
    Semin Oncol; 2008 Aug 15; 35(4):346-55. PubMed ID: 18692685
    [Abstract] [Full Text] [Related]

  • 27. Reversal of FLT3 mutational status and sustained expression of NPM1 mutation in paired presentation, and relapse samples in a patient with acute myeloid leukemia.
    Radojkovic M, Tosic N, Colovic N, Ristic S, Pavlovic S, Colovic M.
    Ann Clin Lab Sci; 2012 Aug 15; 42(2):186-90. PubMed ID: 22585616
    [Abstract] [Full Text] [Related]

  • 28. A clinical grade sequencing-based assay for CEBPA mutation testing: report of a large series of myeloid neoplasms.
    Behdad A, Weigelin HC, Elenitoba-Johnson KS, Betz BL.
    J Mol Diagn; 2015 Jan 15; 17(1):76-84. PubMed ID: 25468431
    [Abstract] [Full Text] [Related]

  • 29. [Identification of molecular markers in children with acute myeloid leukemia (AML)].
    Ilenčíková D, Sýkora J, Mikulášová Z, Repiská V.
    Klin Onkol; 2012 Jan 15; 25(1):26-35. PubMed ID: 22348217
    [Abstract] [Full Text] [Related]

  • 30. [Correlation of adult AML Npm1 mutations with prognosis and its relationship with gene mutation of FLT3 and CEBPA].
    Bao LY, Wang JS.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb 15; 18(1):19-24. PubMed ID: 20137111
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Molecular and clinicopathologic characterization of AML with isolated trisomy 4.
    Bains A, Lu G, Yao H, Luthra R, Medeiros LJ, Sargent RL.
    Am J Clin Pathol; 2012 Mar 15; 137(3):387-94. PubMed ID: 22338050
    [Abstract] [Full Text] [Related]

  • 33. Gene expression profiling in acute myeloid leukaemia (AML).
    Bacher U, Kohlmann A, Haferlach C, Haferlach T.
    Best Pract Res Clin Haematol; 2009 Jun 15; 22(2):169-80. PubMed ID: 19698926
    [Abstract] [Full Text] [Related]

  • 34. Translational implications of somatic genomics in acute myeloid leukaemia.
    Meyer SC, Levine RL.
    Lancet Oncol; 2014 Aug 15; 15(9):e382-94. PubMed ID: 25079101
    [Abstract] [Full Text] [Related]

  • 35. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.
    Fröhling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K.
    J Clin Oncol; 2004 Feb 15; 22(4):624-33. PubMed ID: 14726504
    [Abstract] [Full Text] [Related]

  • 36. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.
    Szankasi P, Ho AK, Bahler DW, Efimova O, Kelley TW.
    Leuk Res; 2011 Feb 15; 35(2):200-7. PubMed ID: 20970189
    [Abstract] [Full Text] [Related]

  • 37. Comparing apples and oranges in normal karyotype acute myeloid leukemia.
    Medeiros BC.
    J Clin Oncol; 2009 Jan 20; 27(3):474; author reply 474-6. PubMed ID: 19075259
    [No Abstract] [Full Text] [Related]

  • 38. Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways.
    Kohlmann A, Bullinger L, Thiede C, Schaich M, Schnittger S, Döhner K, Dugas M, Klein HU, Döhner H, Ehninger G, Haferlach T.
    Leukemia; 2010 Jun 20; 24(6):1216-20. PubMed ID: 20428199
    [No Abstract] [Full Text] [Related]

  • 39. A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics.
    Huang Q, Chen W, Gaal KK, Slovak ML, Stein A, Weiss LM.
    Br J Haematol; 2008 Jul 20; 142(3):489-92. PubMed ID: 18477048
    [No Abstract] [Full Text] [Related]

  • 40. Higher lipocalin 2 expression may represent an independent favorable prognostic factor in cytogenetically normal acute myeloid leukemia.
    Yang WC, Lin PM, Yang MY, Liu YC, Chang CS, Chou WC, Hsu JF, Huang CT, Cho SF, Yu WH, Lin SF.
    Leuk Lymphoma; 2013 Aug 20; 54(8):1614-25. PubMed ID: 23150981
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.